Loading, Please Wait...
SAN FRANCISCO, March 04, 2019 (GLOBE NEWSWIRE) -- Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced that Frank J. Bellizzi, DMD, Chief Executive Officer of Concentric Analgesics, will present at the Cowen 39th Annual Healthcare Conference on Monday, March 11, 2019 at 2:00 pm ET at the Boston Marriott Copley Place.
The presentation slides will be available on the Company’s website, www.concentricanalgesics.com, following Dr. Bellizzi’s presentation.
About Concentric Analgesics, Inc.
Concentric Analgesics is a clinical-stage, biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics. The Company’s portfolio of proprietary TRPV1-agonist prodrugs is designed to provide long-lasting, selective pain relief after a single local administration. Concentric has three active programs for multiple indications with significant unmet need: post-surgical pain, osteoarthritis and chronic refractory pain. Its lead candidate for post-surgical pain, CA-008, is undergoing Phase 2 clinical studies and has received both Breakthrough Therapy Designation and Fast-Track Designation from the US Food and Drug Administration. Concentric is headquartered in San Francisco, California. For more information, please visit www.concentricanalgesics.com.
Wheelhouse Life Science Advisors